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2 cycles of chemotherapy. Common non-hematologic toxicities of all 
grades during consolidation chemotherapy were anorexia(45%), alope-
cia(41%), asthenia(35%), and esophagitis(41%). Hematologic toxicities 
were mild. Although Grade 3-4 neutropenia occurred in 5 cycles out of 
65 cycles, there was no treatment-related mortality 
Conclusions: These results suggest that CCRT with weekly docetaxel 
and cisplatin is feasible and consolidation chemotherapy with same 
agents after CCRT is also well tolerated. Further data will be updated 
on presentation.
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Background: Concurrent chemoradiotherapy (chemoRT) is the pre-
ferred treatment for patients with unresectable stage III NSCLC. Lim-
ited safety information is available on the use of concurrent docetaxel, 
carboplatin and thoracic RT. We report the safety information on the 
initial 100 patients (pts) treated with this chemoRT as part of an ongo-
ing US randomized web-based phase III trial (D0410) evaluating the 
role of erlotinib/placebo following this concurrent chemoRT treatment. 
The sample size is 400 pts and the primary endpoint is progression-free 
survival.
Methods: Pts with unresectable pathologically conﬁrmed stage III 
NSCLC are randomized to receive either erlotinib 150 mg or placebo 
orally daily for 2 years following concurrent chemoRT with docetaxel 
20 mg/m2, carboplatin AUC=2 intravenously weekly for 6 wks with 
thoracic RT of at least 61 Gy in 33 fractions over 6.5 weeks. The 
planned total lung volume exceeding 20 Gy (V20) was less than 32%. 
Only the chemoradiation safety information is being reported. This data 
was reviewed by an independent safety and data monitoring committee.
Results: Pt characteristics; 59% males, median age 69 years (range 38 
to 86), 21% adenocarcinoma, 48% squamous cell, 94% ECOG PS0-1, 
49% stage IIIA, 15% weight loss ≥ 10%. Of 600 planned chemotherapy 
treatments, 500 were administered (93 wk 1, 86 wk 2, 83 wk 3, 82 wk 4, 
80 wk 5, 76 wk 6). There were 27 chemotherapy dose reductions; most 
commonly for esophagitis (8), neutropenia (5), renal dysfunction (3), hy-
persensitivity (2). There were no treatment-related deaths. There were 28 
grade 3 and 3 grade 4 treatment-related adverse events. The most com-
mon grade 3/4 events were esophagitis (7), fatigue (3), dysphagis (2), 
odynophagia (2), neutropenia (1), thrombocytopenia (1), dematitis (1).
Conclusions: This concurrent chemoradiation regimen appears to be 
safe. Enrollment to the phase III trial continues. There is a planned 
interim efﬁcacy evaluation at 150 events (deaths or disease progres-
sion). Funded in part by Sanoﬁ-Aventis, Genentech, and OSI Pharma-
ceuticals.
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Purpose and Objective(s): To assess the incidence and severity of 
acute esophageal reactions from concurrent chemotherapy and 3-di-
mensional proton beam therapy (PBT) in the context of previous results 
with concurrent chemotherapy and 3-dimensional photon therapy (XT) 
for NSCLC.
Materials and Methods: Twenty-ﬁve consecutive patients with NSC-
CL (stages IIB [1], IIIA [8], IIIB [8], IV [2], post-operative recurrent 
[6], underwent PBT and concurrent chemotherapy with curative intent 
on IRB approved protocols. Chemotherapy was platinum-based in all 
patients, most frequently carboplatin/paclitaxel (16 patients). There 
were 16 males/9 females ranging in age from 49 to 81 years (median 
67 years). Histopathologic diagnosis was squamous cell carcinoma in 9 
and non-squamous in 16 patients. All patients were evaluable for acute 
(< or = 90 days from ﬁrst treatment) reactions. Toxicity was based on 
NCI common toxicity criteria vs. 3.0. XT comparisons were based on 
published data from our institution (215 patients) (Wei X et al, Int J 
Radiat Oncol Biol Phys 2006)
Results: Total doses with PBT ranged from 63 cobalt-gray equivalent 
(CGE) (using RBE of 1.1 vs. cobalt gamma rays) to 74 CGE (60-69.6 
Gy with XT) in 33 to 37 fractions (30-58 fractions with XT). The 
median total dose was 74 CGE vs. 63 Gy for XT. Acute esophageal 
reactions were observed in 60% of PBT patients (200 of 215/93% with 
XT). Seven (28%) of patients had grade 2 esophageal reactions (97 of 
215/45.1% with XT). Four (16%) of patients had grade 3 esophageal 
reactions (43 of 215/20.0% with XT). No patient had a grade 4 reaction 
(1of 215/0.5% with XT).
Conclusions: Proton beam therapy permitted higher total doses (17%+) 
with concurrent chemotherapy yet were associated with reduced 
esophageal reactions compared with 3-dimensional conformal photon 
therapy.
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Purpose: Concurrent chemoradiotherapy has become the standard 
treatment for unresectable locally advanced non-small cell lung cancer 
(NSCLC). However, distant metastases remain the major site of failure. 
Here we report a randomized phase II trial of consolidation chemother-
apy with monthly paclitaxel and cisplatin (PC) or observation after con-
current chemoradiotherapy in patients with locally advanced NSCLC to 
evaluate the feasibility and the role of consolidation chemotherapy.
Methods: Between March 2000 and August 2002, a total of 104 
unresectable stage III NSCLC patients who showed at least minimal 
response (6 complete, 86 partial, and 12 minimal responses) after 
concurrent chemoradiotherapy were randomized to receive 3 cycles of 
consolidation chemotherapy (n=50) or to be observed (n=54). Con-
current chemoradiotherapy consisted of weekly paclitaxel 40 mg/m2 
and cisplatin 20 mg/m2 plus thoracic radiation (total dose of 70.2 Gy). 
Consolidation chemotherapy with paclitaxel 135 mg/m2 and cisplatin 
60 mg/m2 started 4 weeks after completion of concurrent chemoradio-
therapy and repeated every 4 weeks. 
Results: With a median follow-up of 41 months, there were no signiﬁ-
cant differences in progression-free survival (PFS) and overall survival 
(OS) between consolidation and observation groups (median PFS, 13 
vs. 12 months; median OS, 19 vs. 24 months). During consolidation 
PC, grade 3 or 4 neutropenia was observed in 29% of the patients. 
However, there was no episode of febrile neutropenia. 
Conclusions: Consolidation chemotherapy with monthly PC after con-
current chemoradiotherapy is feasible and generally tolerable, however, 
does not show a survival beneﬁt in locally advanced
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Background: Some papers report that tumor volume is a signiﬁcant 
prognostic factor in thoracic radiotherapy for non-small-cell lung can-
cer (NSCLC) patients. The purpose of this study is to investigate and 
conﬁrm the impact of total tumor volume(TTV) on survival in patients 
with stage III NSCLC treated with thoracic radiotherapy and concur-
rent chemotherapy.
Methods: From prospectively maintained database of our department, 
sixty patients were identiﬁed who underwent thoracic radiotherapy 
and concurrent chemotherapy in stage III NSCLC patients with an age 
under 75 year between October 2002 and December 2005. All patients 
underwent a CT scanning to facilitate treatment planning. TTV were 
calculated by the three-dimensional radiotherapy planning system. The 
median follow-up duration was 21 months in surviving patients. The 
Kaplan-Meier method, the log rank test and the Cox proportional haz-
ard model were used for evaluation of survival. Survival was updated 
on March 1,2007.
Results: The patients consisted of 47 males and 13 females in gender, 
64 year old of median age (range 44-75), 27 IIIA and 33 IIIB in TNM 
staging, 24 squamous cell carcinoma, 30 adenocarcinoma and 6 oth-
ers in histology and 39 PS 0, 19 PS1, 2 PS2 in performance status, 
respectively. TTV was ranged between 11 and 1512 cc (median 78.5 
cc). A prescribed dose of radiotherapy was 60 Gy in 30 fractions using 
4-,6- or 10-MV X-rays in all patients. Chemotherapy regimens were 
as follows: 1) weekly paclitaxel (TXL)+ weekly carboplatin(CBDCA) 
consolidation CBDCA + TXLx2 in 33 patients, 2) mitomycin C + vin-
desine+ cisplatin x 4 in 12, 3)cisplatin+vinorelbinex4 in 8 and 4)others 
in 7. The overall 2-year survival rate was 66 %. In patients with larger 
TTV than median TTV 78.5 cc and with smaller TTV, the overall 2-
year survival rates were 52% and 80%, respectively. The median over-
all survival was 29 months. The median overall survival with smaller 
TTV is not mature enough to be evaluated. On univariate analysis, 
stage IIIA was signiﬁcantly better prognostic factor than IIIB (P=0.042) 
and the survival with smaller TTV tends to be favorable (P=0.056). PS 
(P=0.908) and gender (P=0.356) were not signiﬁcant. On multivari-
ate analysis, there was tendency of favorable survival in smaller TTV 
(P=0.068) and others (stage, PS, gender) were not signiﬁcant.
Conclusion: TTV is an independent prognostic factor in stage III 
NSCLC treated with concurrent chemoradiotherapy.
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Background: The optimal duration of chemotherapy for advanced 
non-small cell lung cancer (NSCLC) is unclear. We performed a sys-
tematic review and meta-analysis of published randomized controlled 
trials (RCT) comparing longer versus shorter durations of chemo-
therapy. 
Methods: We searched MEDLINE, EMBASE and CENTRAL for 
RCTs comparing 1) a deﬁned number of cycles of chemotherapy versus 
continuing until disease progression, 2) a deﬁned number of cycles 
versus a higher number of cycles of the same chemotherapy and, 3) a 
deﬁned number of cycles of initial chemotherapy vs the same initial 
chemotherapy followed by additional cycles of a different chemo-
therapy. The primary outcome was overall survival (OS). Secondary 
outcomes included progression-free survival (PFS), adverse events 
(AE), and quality of life (QL). Hazard ratios (HR), conﬁdence intervals 
(CI) and p-values (p) were estimated with ﬁxed effects models using 
Revman 4.2.8
